Literature DB >> 7034809

Immunologic classification of lymphocytic leukemias based on monoclonal antibody-defined cell surface antigens.

R W Schroff, K A Foon, R J Billing, J L Fahey.   

Abstract

A panel of monoclonal antibodies reactive with normal lymphocyte subsets was used to classify cases of lymphocytic leukemia on the basis of cell surface antigen expression. The antibodies employed were commercially available and included a common framework HLA-DR antibody, two pan-T antibodies (Leu-1 and OKT-3), and antibodies defining cytotoxic/suppressor (Leu-2 and OKT-8) and helper/inducer (Leu-3 and OKT-4) subpopulations of normal T lymphocytes. Cases of ALL could be subgrouped into non-T non-B, pre-T and T-ALL on the basis of reactivity with HLA-DR, Leu-1, and OKT-3 antibodies. Leukemic cells from patients with T-cell CLL could be divided into Leu-2/OKT-8 reactive and Leu-3/OKT-4 reactive subpopulations, as well as a subgroup in which the majority of cells were unreactive with either of these antibodies. With the exception of one individual, all Sézary cell leukemias expressed a phenotypic pattern similar to that of the Leu-3 subgroup of T-CLL. Malignancies of B-cell lineage (B-CLL, prolymphocytic leukemia, and lymphosarcoma) that were examined were reactive with both the HLA-DR and Leu-1 antibodies. On the contrary, normal B lymphocytes and lymphoid cell lines of B-cell origin did not express surface antigens recognized by the Leu-1 antibody.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7034809

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Appearance of the T-cell marker CD8 on B chronic lymphatic leukemia cells in long-term cultures.

Authors:  R Farkas; S Ben-Efraim; Y Manor; I Zan-Bar; A Klajman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Modified immunocytochemical slide technique for demonstrating surface antigens on viable cells.

Authors:  N Frickhofen; K J Bross; W Heit; H Heimpel
Journal:  J Clin Pathol       Date:  1985-06       Impact factor: 3.411

3.  Induction of plasmacytoid differentiation by phorbol ester in B-cell lymphoma cell lines bearing 8;14 translocations.

Authors:  D Benjamin; I T Magrath; T J Triche; R W Schroff; J P Jensen; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 4.  Cytochemistry of lymphoid cells: a review of findings in the normal and leukaemic state.

Authors:  A D Crockard
Journal:  Histochem J       Date:  1984-10

5.  Production of pemphigus antibody in vitro and analysis of T-cell subsets.

Authors:  A R Ahmed; R I Murahata; R W Schroff; R M Stevens; A S Saxon
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

6.  Crossreaction of monoclonal anti-T-cell antibodies: implications for classifying B-cell leukemias.

Authors:  R Munker; E Thiel; U Kummer; H Rodt; S Thierfelder
Journal:  Blut       Date:  1983-02

7.  Expression of a T-cell antigen (Leu-1) by B-cell lymphomas.

Authors:  B F Burns; R A Warnke; R S Doggett; R V Rouse
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

8.  Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies.

Authors:  P L Tazzari; M Gobbi; A Dinota; A Bontadini; G Grassi; C Cerato; M Cavo; S Pileri; F Caligaris-Cappio; S Tura
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

9.  Reactivity of Leu 1 and T101 monoclonal antibodies with B cell lymphomas (correlations with other immunological markers).

Authors:  T Al Saati; G Laurent; P Caveriviere; F Rigal; G Delsol
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

10.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse.

Authors:  S H Swerdlow; J A Habeshaw; L J Murray; H S Dhaliwal; T A Lister; A G Stansfeld
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.